Matteo Serenelli
Overview
Explore the profile of Matteo Serenelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erriquez A, Leistner D, Paradies V, Pavasini R, Serenelli M, Casella G, et al.
Catheter Cardiovasc Interv
. 2025 Mar;
PMID: 40065569
Background: There is limited evidence on the safety and efficacy of biodegradable-polymer sirolimus-eluting ultra-thin stent (BP-SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). Aims: This...
2.
Bianchi N, Frascaro F, Zanarelli L, Marchini F, Sanguettoli F, Meossi S, et al.
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860474
The detection of unexpected findings (UF) during CT scans of patients undergoing TAVR is frequent; however, it is unclear whether such findings have a clinical impact on the TAVR pathway....
3.
Serenelli M, Cantone A, Dal Passo B, Sanguettoli F, Fabbri G, Colombi G, et al.
J Cardiovasc Med (Hagerstown)
. 2025 Jan;
26(2):81-87.
PMID: 39841913
Introduction: Cardiac amyloidosis typically causes restrictive cardiomyopathy, in which the impairment of diastolic function is dominant. Echocardiography provides prognostic information through some important parameters: left ventricular ejection fraction (LVEF) and...
4.
Porcari A, Razvi Y, Cappelli F, Nitsche C, Serenelli M, Longhi S, et al.
JAMA Cardiol
. 2025 Jan;
PMID: 39841451
Importance: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration. Objective:...
5.
Porcari A, Chimenti C, Merlo M, Musca F, Vergaro G, Iacoviello M, et al.
G Ital Cardiol (Rome)
. 2024 Nov;
25(12):900-920.
PMID: 39588628
The perspective on cardiac amyloidosis has deeply changed over the last 10 years following major advances in diagnosis and treatment options. This heterogeneous disease requires the interaction among experts of...
6.
Tini G, Musumeci B, Milani P, Zampieri M, Caponetti A, Fabris F, et al.
ESC Heart Fail
. 2024 Sep;
12(1):379-388.
PMID: 39301748
Aims: Disease staging and prognostic scoring in wild-type transthyretin-related cardiac amyloidosis (ATTRwt-CA) can be captured by two systems (NAC and Columbia scores). However, uncertainty remains as epidemiology of the disease...
7.
Campo G, Bohm F, Engstrom T, Smits P, Elgendy I, McCann G, et al.
Circulation
. 2024 Sep;
150(19):1508-1516.
PMID: 39217603
Background: Complete revascularization is the standard treatment for patients with ST-segment-elevation myocardial infarction and multivessel disease. The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) confirmed...
8.
Longhi S, Biagini E, Guaraldi P, Carigi S, Curro Dossi M, Bartolotti M, et al.
J Cardiovasc Med (Hagerstown)
. 2024 Jul;
25(9):682-692.
PMID: 39083075
Aims: Transthyretin cardiac amyloidosis (ATTR-CA) is a rare and progressive cardiomyopathy caused by amyloid fibril deposition in myocardial tissue. Diagnostic challenges have historically hampered timely detection. Recent advances in noninvasive...
9.
Tebaldi M, Gallo F, Scoccia A, Durante A, Tedeschi D, Verdoliva S, et al.
Rev Cardiovasc Med
. 2024 Jul;
24(2):62.
PMID: 39077421
Background: Recently, questions around the efficacy and effectiveness of Fractional Flow Reserve (FFR) have arisen in various clinical settings. Methods: The Clinical Outcome of FFR-guided Revascularization Strategy of Coronary Lesions...
10.
Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al.
J Am Coll Cardiol
. 2024 Jun;
83(24):2411-2422.
PMID: 38866445
Background: Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Objectives: This study sought to assess the effectiveness and tolerability of SGLT2i...